Gross Profit Trends Compared: Vertex Pharmaceuticals Incorporated vs Walgreens Boots Alliance, Inc.

Vertex's explosive growth vs Walgreens' steady profits

__timestampVertex Pharmaceuticals IncorporatedWalgreens Boots Alliance, Inc.
Wednesday, January 1, 201451942800021569000000
Thursday, January 1, 201590679400026753000000
Friday, January 1, 2016149171700029874000000
Sunday, January 1, 2017221353300029162000000
Monday, January 1, 2018263805800030792000000
Tuesday, January 1, 2019361506300028159000000
Wednesday, January 1, 2020546938300026077000000
Friday, January 1, 2021667020000028067000000
Saturday, January 1, 2022785040000028266000000
Sunday, January 1, 2023860700000027072000000
Monday, January 1, 2024948960000026524000000
Loading chart...

Cracking the code

Gross Profit Trends: Vertex Pharmaceuticals vs Walgreens Boots Alliance

In the ever-evolving landscape of the pharmaceutical and retail sectors, understanding financial trends is crucial. Over the past decade, Vertex Pharmaceuticals Incorporated has shown a remarkable growth trajectory in gross profit, increasing from approximately $519 million in 2014 to an impressive $8.6 billion by 2023. This represents a staggering growth of over 1,500%, highlighting Vertex's strategic advancements in the biotech industry.

Conversely, Walgreens Boots Alliance, Inc., a giant in the retail pharmacy sector, has maintained a steady gross profit, fluctuating around the $27 billion to $31 billion mark during the same period. Despite the stability, Walgreens' gross profit saw a slight decline in 2023, indicating potential challenges in the retail market.

This comparison underscores the dynamic nature of these industries, with Vertex's innovative edge driving its financial success, while Walgreens navigates the complexities of retail pharmacy.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025